On Monday, Myriad Genetics Inc. announced the failure of Flurizan in Phase III trials. This news follows the results from the LEADe study showing the cholesterol drug Lipitor did not benefit Alzheimer's patients, and the failure of Alzhemed in Phase III trials last year.
With all this disappointing news, it seems more important than ever for professionals, with input from patients and their families, to talk about new approaches to Alzheimer's research and care. Maybe implementing some of the ideas discussed at the National Institute on Aging 2006 conference would help. I'll be at ICAD (the International Conference on Alzheimer's disease) in late July - it will be interesting to see whether new approaches are widely discussed.